

correlated the changes in impedance values with alterations in the thoracic fluid volume due to pulmonary or cardiac problems. It is suggested that the measurement of T.E.I. is a promising method for the early detection of increased pulmonary fluid volume but that it needs further objective verification in man.

This study was supported by the All India Institute of Medical Sciences, the Directorate General Armed Forces Medical Services, and the Indian Council of Medical Research, New Delhi.

We are grateful to Lt.-Gen. S. N. Chatterjee, Director-General Armed Forces Medical Services, and Lt.-Gen. Ved Prakash, Director Medical Services (Army), and their staff for ungrudging support during all phases of the study.

References

- Allison, R. D., Holmes, E. L., and Nyboer, J. (1964). *Journal of Applied Physiology*, **19**, 166.
 Bhatia, M. L., et al. (1969). *British Medical Journal*, **2**, 551.
 Bhatia, M. L., et al. (1972). In *Advances in Medicine*, ed. R. Vishwanathan, p. 466. Bombay, Association of Physicians of India.
 Hurtado, A. (1964). In *Handbook of Physiology, Section 4*, ed. D. B. Dill, E. F. Adolph, and C. G. Wilber, p. 849. Washington, American Physiological Society.
 Pomerantz, M., Delgado, P., and Eiseman, B. (1970). *Annals of Surgery*, **171**, 686.
 Roy, S. B., et al. (1968). *Nature*, **217**, 1177.
 Roy, S. B., et al. (1969). *British Heart Journal*, **31**, 52.
 Van De Water, J. M., et al. (1970). *Journal of Thoracic and Cardiovascular Surgery*, **60**, 641.
 Van De Water, J. M., et al. (1973). *Chest*, **64**, 597.

Hypouricaemia and Proximal Renal Tubular Dysfunction in Acute Myeloid Leukaemia

M. AFZAL MIR, I. W. DELAMORE

British Medical Journal, 1974, **3**, 775-777

Summary

Two patients with acute myeloid leukaemia developed hypouricaemia during the period of their illness. Renal clearance studies showed that the hypouricaemia was associated with an increased urate clearance, renal aminoaciduria, and an episodic increase in phosphate clearance. These findings together with an inadequate suppression of urinary urate excretion after the administration of pyrazinamide suggest proximal tubular dysfunction affecting reabsorption of a wide variety of substances. Ten more patients with acute leukaemia were studied and the results indicate that this lesion develops in a large proportion of patients with acute myeloid leukaemia.

Introduction

An increase in the serum urate level is a common finding in acute leukaemia and lymphoma (Weisberger and Perksy, 1953; Gold and Fritz, 1957; Kritzer, 1958). Hypouricaemia is an unexpected development in diseases characterized by an increase in uric acid production. The case reports of two patients with acute myeloid leukaemia in whom serum uric acid concentration fell below 2 mg/100 ml during the course of their illness are presented. Renal clearance studies and amino-acid chromatography showed proximal tubular dysfunction with some features normally seen in association with the adult Fanconi syndrome (Leaf, 1966).

Methods

Inorganic phosphorus was estimated by the method of Gomorri (1942) using *p*-dimethylaminophenol sulphate as reducing agent. Uric acid and creatinine concentrations were estimated in a Technicon AutoAnalyzer. Paper chromatography was

performed on the original urine and the extent of aminoaciduria was assessed by visual comparison of the specks with the known spots of various amino-acids. Plasma amino-acid levels were determined by ion-exchange chromatography (Thomas, 1970). Three-hour clearances were performed before and after the administration of pyrazinamide to assess the tubular reabsorption of urate. A high intake of oral fluids was maintained to facilitate spontaneous voiding. Urinary and serum lysozyme concentrations were determined by the turbidimetric method of Parry et al. (1965). Other investigations were performed by standard laboratory methods.

Case Reports

CASE 1

A 58-year-old woman was admitted to hospital with pallor and moderate hepatosplenomegaly. Haematological studies showed a white cell count of 2,800/mm³ (15% were blast cells), a haemoglobin level of 9.1 g/100 ml, and a platelet count of 91,000/mm³. A marrow aspirate was hypercellular with 90% myeloblasts. Serum albumin was 3.5 g/100 ml, serum globulin 3.9 g/100 ml, serum vitamin B₁₂ 277 pg/ml, serum calcium 9.6 mg/100 ml, and serum inorganic phosphorus 3.4 mg/100 ml. Serum and urinary muramidase (lysozyme) concentrations were 4.2 µg/ml (normal 3-13 µg/ml) and 2.5 µg/ml (normal <2 µg/ml) respectively. The blood urea was 28 mg/100 ml, and three daily serum urate estimations ranged from 4.6 to 5.2 mg/100 ml (average 4.9 mg/100 ml). Serum transaminases, bilirubin, alkaline phosphatase, and electrolytes were normal. A 24-hour phosphate clearance was 9 ml/min with a phosphate clearance to creatinine clearance ratio of 0.11 (normal <0.2; Nordin and Fraser, 1960). There was no glucosuria, no Bence Jones proteinuria, and the urinary amino-acid chromatographic pattern was normal.

A five-day course of cytotoxic therapy consisting of a single intravenous administration of daunorubicin (1.5 mg/kg body weight) and five daily intravenous injections of cytarabine (2 mg/kg body weight) was begun on the third day in hospital. Serum urate was 4 mg/100 ml and fell to 1.3 mg/100 ml two days after the second course of chemotherapy. The results of urate and creatinine clearance studies are shown in table I. Serum calcium was 8.6 mg/100 ml and serum inorganic phosphorus 2.2 mg/100 ml. A 24-hour phosphate clearance was 45 ml/min with a phosphate clearance to creatinine clearance ratio of 0.95. There was no glucosuria. Paper chromatography showed a generalized aminoaciduria. The arterial blood pH was 7.44 and serum bicarbonate 28 mEq/l. An acid load of 0.1 g/kg body weight of ammonium chloride produced a minimum urinary pH of 5.3 (normal pH <5.3; Wrong and Davies, 1959). Serum potassium fell to 3.2 mEq/l. The mean daily potassium output was 42 mEq against an intake of 48 mEq.

University Department of Clinical Haematology, Manchester Royal Infirmary, Manchester M13 9WL

M. AFZAL MIR, M.R.C.P., D.C.H., Registrar
 I. W. DELAMORE, PH.D., F.R.C.P., Physician in Charge

TABLE I—Results of Creatinine and Urate Clearance Studies in Two Patients with Acute Myeloid Leukaemia. Control Values are Means (\pm S.D.) derived from Seven Subjects

	Control Values	Case 1			Case 2		
		On Admission	After Therapy	After Remission	On Admission	After Therapy	After 10 Weeks
Serum Level (mg/100 ml):							
Urate	5.5 \pm 1.5	4.8	1.3	5.0	2.5	1.7	1.8
Creatinine	1.02 \pm 0.09	1.0	0.8	0.9	0.8	0.7	0.8
Blood urea (mg/100 ml)	15-40	28	8	32	20	26	23
Urinary excretion:							
Creatinine (g/24 hr)	1.03 \pm 0.02	1.10	0.56	0.72	1.18	1.9	1.17
Urate (mg/min)	0.49 \pm 0.0004	0.42	0.30	0.60	0.75	0.80	0.41
Clearance (ml/min/1.73 m ²):							
Creatinine	88.16 \pm 5.1	81	47	83	95	203	112
Urate	9.2 \pm 1.1	8.3	24	7.8	32	52	25
Filtered Urate (mg/min)	10.71 \pm 1.07	5.4	0.61	4.0	2.3	3.4	2.0
Cur/Ccr \times 100	9.7-11	10.2	51	9.3	51	25	22
UurV \times 100/Fur	8.8-14	7.7	49	9.2	32	11	20

Cur/Ccr = Urate/creatinine. UurV/Fur = excreted urate/filtered urate.

TABLE II—Serum and Urine Values in Case 2 before and after Pyrazinamide 3 g orally

	Before	After
Serum uric acid (mg/100 ml)	1.6	1.5
Urinary excretion (mg/min):		
Urate	0.75	0.34
Creatinine	1.1	0.9
Clearance (ml/min/1.73 m ²):		
Urate	54	25
Creatinine	134	98

During the next 18 days serum urate ranged from 1 to 2.1 mg/100 ml. Daily urate and creatinine clearance studies showed a persistently high urate clearance. The phosphate clearance fluctuated between 6 and 42 ml/min but remained below 10 ml/min after the 30th day in hospital.

A bone marrow remission was achieved in the sixth week. The ratio of the excreted urate to the filtered urate (UurV \times 100/Fur) fell from 49% to 9.2% after remission and the serum uric acid level increased to 5 mg/100 ml (table I). The urinary amino-acid chromatographic pattern returned to normal.

CASE 2

A 50-year-old woman was admitted with weakness and marked hepatomegaly. Initial investigations showed a haemoglobin level of 7 g/100 ml and a white cell count of 7,200/mm³ with 34% blast cells. A marrow specimen contained 60% myeloblasts. Serum albumin was 3.8 g/100 ml, serum globulin 3.3 g/100 ml, and blood urea 20 mg/100 ml with a 24-hour phosphate clearance of 6 ml/min. Serum calcium was 9.6 mg/100 ml and serum phosphate 3.7 mg/100 ml. Serum electrolytes, bilirubin, alkaline phosphatase, and transaminases were within normal limits. A urinalysis of a freshly voided specimen showed a pH of 5, 1% sugar, and a normal amino-acid chromatographic pattern. The 24-hour urinary protein excretion was 185 mg and immunoelectrophoresis did not show the presence of Bence Jones protein. The fasting blood sugar level was 165 mg/100 ml and three determinations of serum uric acid ranged from 2.5 to 3.5 mg/100 ml.

Additional investigations showed a serum muramidase concentration of 23 μ g/ml, a urinary muramidase concentration of 1 μ g/ml, and a diabetic glucose tolerance curve.

Three days after the first course of cytotoxic therapy serum urate fell to 1.7 mg/100 ml, serum calcium to 8.8 mg/100 ml, and serum inorganic phosphorus to 2.7 mg/100 ml, and a 24-hour phosphate clearance increased to 30 ml/min with a phosphate clearance to creatinine clearance ratio of 0.14. Paper amino-acid chromatography now showed the presence of a generalized aminoaciduria and the 24-hour urinary protein excretion reached a maximum of 1.2 g, with a predominant electrophoretic mobility in the albumin and α_2 -globulin regions. The arterial blood pH was 7.42 and the urine pH after an acid load was 5.1. Plasma bicarbonate was 26 mEq/l. The urate and creatinine clearance data are shown in table I.

The effect of pyrazinamide was studied and the results are shown in table II. Plasma amino-acid concentrations were found to be within normal limits. The mean daily urinary potassium was 98 mEq against a mean intake of 57 mEq/day.

She was followed up as an outpatient for 18 weeks and repeated estimations of serum urate ranged from 0.8 to 1.8 mg/100 ml. The ratio of the excreted urate to that of the filtered urate remained high (table I) but phosphate clearance showed wide fluctuations from 32 ml/min in the 14th week to 8 ml/min in the 16th week. A generalized aminoaciduria was found to be present on each visit. The administration of pyrazinamide produced only a 34% reduction (normal > 80%; Steele and Rieselbach, 1967) in urate excretion in the 14th week.

OTHER CASES

The data from these two patients suggested an impairment in renal tubular reabsorption of urate, phosphate, and amino-acids. Ten consecutive patients with acute leukaemia were studied to investigate whether proximal tubular dysfunction occurred as a part of the disease. Urate clearance was found to increase in all the 10 patients. The serum uric acid level increased in two patients with acute lymphoblastic leukaemia and fell in the other eight patients with acute myeloid leukaemia (table III). Hypouricaemia developed in two of these patients (cases 5 and 11). A variable increase in phosphate clearance occurred in all patients after antileukaemic therapy.

TABLE III—Two Sets of Renal Clearance Data (before and after Cytotoxic Therapy) for each of 10 Patients with Acute Leukaemia

Case No.	Diagnosis (Acute Leukaemia)	Days after Diagnosis	Serum Urate (mg/100 ml)	Blast Cell Count $\times 10^3$	Urinary Urate (mg/min)	Clearance (ml/min/1.73 m ²)	
						Urate	Creatinine
3	Myeloblastic	2	6.6	0.7	0.29	4.4	42
		8	2.3	0.2	0.88	42	110
4	Myelomonocytic	6	6.2	83.2	0.70	11	73
		10	5.6	1.18	1.30	23	162
5	Myeloblastic	1	3.5	2.8	0.36	10	56
		31	1.7	None	0.56	32	80
6	Myelomonocytic	2	3.8	5.28	0.43	9.8	89
		7	4.6	0.03	0.60	17	97
7	Myeloblastic	4	3.9	5.12	0.26	7.3	83
		17	2.7	None	0.85	35	70
8	Lymphoblastic	2	8.1	20.3	0.72	9.5	45
		8	12	0.48	2.90	26.4	60
9	Myelomonocytic	2	20	45	0.45	2.3	45
		10	7	None	1.60	23	46
10	Myelomonocytic	3	4.5	14	0.33	6.5	84
		6	4.3	?	1.80	38	190
11	Myeloblastic	6	4.8	5	0.72	17	117
		9	1.7	3.4	1.08	72	134
12	Lymphoblastic	8	5.3	15.1	0.29	5.4	41
		11	7.1	7.9	0.84	12	57

A generalized aminoaciduria developed in two patients (cases 3 and 11) before cytotoxic drugs had been started. In three other patients (cases 5, 7, and 9) aminoaciduria appeared during the first course of antileukaemic therapy. Plasma amino-acids were determined in case 7 and found to be within normal limits. The pyrazinamide suppression test was used in six patients (cases 3, 5, 7, 9, 10, and 11), and there was only a partial suppression (average 54%) in the prepyrazinamide urinary urate excretion in three patients (cases 3, 7, and 9) and an average of 34% suppression in cases 5 and 11. These results indicate an incomplete tubular reabsorption of urate. Case 10 showed a normal response to the administration of pyrazinamide with more than 80% reduction in urinary urate excretion.

Up to the time of writing a haematological remission was achieved in cases 3 and 5 after five and nine courses of chemotherapy respectively. Both these patients continued to receive monthly maintenance cytotoxic therapy. Serum urate increased to over 5 mg/100 ml and there was a normal response to the pyrazinamide suppression test in both cases. The abnormal urinary amino-acid chromatographic pattern persisted in case 5, however.

Of the seven patients (cases 1, 2, 3, 5, 7, 9, and 11) showing evidence of proximal tubular dysfunction two (cases 3 and 11) developed the renal lesion before the administration of any drugs.

Discussion

Hypouricaemia was an unexpected development since in both of the patients described there was a heavy blast cell infiltration of bone marrow and, presumably, of other organs. Blast cells are a rich source of phosphorus (Rigas *et al.*, 1956) and hyperphosphataemia has been observed after antileukaemic therapy (Zusman *et al.*, 1973). Hyperuricaemia and hyperphosphataemia seem to be more logical sequelae to excessive destruction of tissues rich in nucleoproteins and phosphorus as a result of cytotoxic therapy.

Normally filtered urate is believed to be reabsorbed completely and 5% to 10% of the filtered load is excreted by the distal tubule (Gutman, 1964; Steele and Rieselbach, 1967). Pyrazinamide, a third-line antituberculous drug, has been found to decrease tubular secretion of uric acid (Steele and Rieselbach, 1967; Gutman *et al.*, 1969). Only about 2% of the filtered load of urate is excreted by normal persons after a single dose of 3 g pyrazinamide. In three patients with hypouricaemia (cases 2, 5, and 11) this fraction exceeded 20%. This finding suggests an impairment in the renal tubular reabsorption of the filtered urate.

The fall in the serum urate level in the two patients described here was associated with an increased renal clearance of urate and phosphate. Aminoaciduria developed in five of the other 10 patients studied. Plasma amino-acids were found to be within normal limits in two patients. These data indicate that impaired tubular reabsorption was the major factor responsible for the fall in the serum uric acid level.

These abnormalities outlined are seen in the adult Fanconi syndrome. Additional features associated with the syndrome but not seen in our patients are renal acidosis, glucosuria, and osteomalacia (Wallis and Engle, 1957; Leaf, 1966). The impairment of tubular reabsorption seems to involve mostly urate, phosphate, and presumably potassium—substances which are released from blast cells after effective chemotherapy. Hyperkalaemia leading to hypokalaemia has been observed in 59% of the patients with acute myeloid leukaemia (to be published).

The adult Fanconi syndrome has been reported in association with various malignant states including multiple myeloma (Sirota and Hamerman, 1954) Costanza and Smoller, 1963), ovarian carcinomatosis (Clay *et al.*, 1953), carcinoma of the pancreas (Myerson and Pastor, 1954), and carcinoma of the liver (Stowers and Dent, 1947). Hypouricaemia has been reported in patients with Hodgkin's disease (Bennett *et al.*, 1972) and carcinoma of the lung (Weinstein *et al.*, 1965).

The proximal tubular dysfunction with impaired tubular reabsorption, as indicated by aminoaciduria, a fall in serum urate, and an increase in phosphate clearance, seems to develop

in many more patients with acute myeloid leukaemia than in any other malignant condition so far reported. A high frequency of renal tubular disturbance as seen in this series is suggestive of a causal relationship between the abnormal myeloid cells and the impairment in renal reabsorption. Muggia *et al.* (1969) postulated that muramiduria might be related to hypokalaemia in patients with acute monocytic and myelomonocytic leukaemia. Hypouricaemia was not present in their patients. In one of the two patients described (case 2) the urinary muramidase concentration was within normal limits.

The renal tubular disorder can not be attributed to antileukaemic therapy since in two patients the lesion developed before the administration of these drugs and in two patients the tubular dysfunction improved during remission despite maintenance cytotoxic therapy. The most likely cause for the development of the renal tubular deficit in these patients seems to be the release of unidentified metabolites from the abnormal myeloid cells which may compete for tubular reabsorption with the normal substances in the glomerular filtrate. This view is compatible with the fact that the lesion recovered with the onset of remission in cases 1 and 3. It would also explain the observed variability in the severity of these abnormalities and the fluctuation of phosphate clearance seen in all patients.

Though not attributable to a direct toxic effect of antileukaemic therapy the hypouricaemia develops in most cases after the destruction of abnormal myeloid cells by cytotoxic drugs. Hyperuricaemia certainly occurs in some patients but the incidence of this complication in acute myeloid leukaemia is much lower than is commonly believed. Our studies on the patients presented and on other patients suggest that there is a high frequency of proximal renal tubular dysfunction, which affects reabsorption of urate, in acute myeloid leukaemia. This acts as a "safety valve" and prevents the development of hyperuricaemia.

We thank Dr. A. H. Gowenlock for his co-operation in performing the biochemical investigations, and Dr. B. Fowler and Dr. D. B. Gordon, the Willink Biochemical Genetics Laboratory, Manchester, for estimating plasma amino-acids.

References

- Bennett, J. S., *et al.* (1972). *Annals of Internal Medicine*, **76**, 751.
 Clay, R. D., Darmady, E. M., and Hawkins, M. (1953). *Journal of Pathology and Bacteriology*, **65**, 551.
 Costanza, D. J., and Smoller, M. (1963). *American Journal of Medicine*, **34**, 125.
 Gold, L. G., and Fritz, R.D. (1957). *Annals of Internal Medicine*, **47**, 428.
 Gomorri, G. (1942). *Journal of Laboratory and Clinical Medicine*, **27**, 955.
 Gutman, A. B. (1964). *American Journal of Medicine*, **37**, 833.
 Gutman, A. B., Yu, T. F., and Berger, L. (1969). *American Journal of Medicine*, **47**, 575.
 Krizler, R. A. (1958). *American Journal of Medicine*, **25**, 532.
 Leaf, A. (1966). In *The Metabolic Basis of Inherited Disease*, ed. J. B. Stanbury, J. B. Wyngaarden, and D. S. Fredrickson, 2nd edn., p. 1205. New York, McGraw-Hill.
 Muggia, F. M., *et al.* (1969). *American Journal of Medicine*, **47**, 351.
 Myerson, R. M., and Pastor, B. H. (1954). *American Journal of the Medical Sciences*, **228**, 378.
 Nordin, B. E. C., and Fraser, R. (1960). *Lancet*, **1**, 947.
 Parry, R. M., Jun., Chandan, R. C., and Shahani, K. M. (1965). *Proceedings of the Society of Experimental Medicine*, **119**, 384.
 Rigas, D. A., *et al.* (1956). *Journal of Laboratory and Clinical Medicine*, **48**, 356.
 Sirota, J. H., and Hamerman, D. (1954). *American Journal of Medicine*, **16**, 138.
 Steele, T. H., and Rieselbach, R. E. (1967). *American Journal of Medicine*, **43**, 868.
 Stowers, J. M., and Dent, C. E. (1947). *Quarterly Journal of Medicine*, **16**, 275.
 Thomas, A. J. (1970). In *Automaton, Mechanization and Data Handling in Microbiology*, ed. A. Baillie, and R. J. Gilbert, p. 107. London. Academic Press.
 Wallis, L. A., and Engle, R. L., Jun. (1957). *American Journal of Medicine*, **22**, 13.
 Weisberger, A. S., and Persky, L. (1953). *American Journal of Medical Science*, **225**, 669.
 Weinstein, B., Irreverre, F., and Watkin, D. M. (1965). *American Journal of Medicine*, **39**, 520.
 Wrong, O., and Davies, H. E. F. (1959). *Quarterly Journal of Medicine*, **28**, 259.
 Zusman, J., Brown, D. M., and Nesbit, M. E. (1973). *New England Journal of Medicine*, **289**, 1335.